ArticleJournal of inflammation research2025
Prediction of Flares in Systemic Lupus Erythematosus During Post-Remission Follow-up.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The efficacy and safety of iguratimod treatment in stable systemic lupus erythematosus: a preliminary prospective cohort study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Patients at high risk of SLE flares benefit from being identified before flares; this can be done by predictors of flares. This study aimed to explore the predictive factors and model of SLE flares after remission, providing basis for clinical decision-making. Patients and Methods: SLE patients recruited at the Peking Union Medical College Hospital (PUMCH), were all registered in the Chinese SLE treatment and research (CSTAR) registry cohort and had experienced at least one remission before December 31, 2020. Demographic, clinical, and laboratory parameters were collected through CSTAR online registry. The predictive effects of variables were analyzed using a Cox proportional hazards model. A nomogram was formulated to predict flares. Results: A total of 359 patients were included in the analysis, among which, 108 (30.1%) patients had at least one flare. Multivariate Cox regression model showed that younger age (hazard ratio [HR], 0.97; 95% CI, 0.95-0.99), positive anti-dsDNA at remission (HR, 1.64; 95% CI, 1.08-2.51), significantly low levels of C3 and C4 (HR, 2.09; 95% CI, 1.17-3.73) were independent risk factors associated with flares. A nomogram was established based on the multivariate analysis. The internal bootstrap resampling approach suggested the nomogram has a certain degree of discriminatory power with a C-index of 0.654 (95% CI, 0.601-0.707). The calibration plots also showed good consistency between the prediction and the observation. Conclusion: This study highlights that SLE patients with significantly low levels of C3 and C4, younger age, and elevated anti-dsDNA levels may require closer monitoring and follow-up after remission. Identifying these predictors allows clinicians to better assess the risk of flare and tailor therapeutic strategies accordingly for more effective long-term management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.